In contrast, nivolumab dramatically increases the PBMC recognition and destruction of NSCLC cells carrying C/C genotype, markedly increasing IFN-ɣ-mediated PD-L1 expression because of modulation of the competitive binding of both C/EBPβ and NFIC to PD-L1 promoter/enhancer region (Fig. 9). Here, CEBPB is linked to non-small cell lung carcinoma.